Evidence summary
Proposed assessments cover safety, containment, local activity and durability.
Study population and stages
Protocol v3.0 describes a prospective, open-label, single-arm Phase 1 study in adults with advanced solid tumors outside the skull. Six participants form the initial safety lead-in. After review by an independent data safety monitoring board, enrollment is planned to expand to about 50 participants.
Primary measures
Primary measures include dose-limiting toxicities within 28 days after each session and adverse events, including serious events, through follow-up. The trial assesses local containment using out-of-lesion distribution, delivery stopped under mandatory rules and non-target tissue injury.
How the study assesses local response and symptoms
The protocol plans to assess lesion-level complete non-viable response (CNVR) 7–28 days after the final session. This measure primarily looks for definite signs of remaining viable tumor tissue on contrast imaging. For participants whose visible lesions were all injected, the protocol also evaluates patient-level CNVR. It separately records RECIST 1.1 response and symptoms or functions such as pain, bleeding, eating and breathing.
Imaging review and follow-up
Two readers independently review imaging used to assess response, with a third reader resolving disagreements. The protocol schedules follow-up at months 3, 6, 9 and 12 after the first session to track how long local control lasts and to continue safety assessment.
